2018 TRS Annual Scientific and Business Meeting
OVERVIEW
2018 TRS Annual Scientific and Business Meeting is organized by Tennessee Rheumatology Society (TRS) and will be held during Feb 23 - 24, 2018 at Franklin Marriott Cool Springs, Franklin, Tennessee, United States of America.
The target audience for this medical event is Rheumatologists, physicians engaged in the ongoing practice of rheumatology. This CME Conference has been approved for a maximum of 6.75 AMA PRA Category 1 Credits.
Conference Description :
The purpose is to increase and propagate the understanding of rheumatic diseases among physicians engaged in the ongoing practice of rheumatology and the socio-economic issues involved in the treatment of these diseases, and other lawful purposes; provided, however, that all purposes of the Corporation are and shall remain exclusively charitable, scientific, religious or educational and otherwise within the meaning of Section 501(c)(3) corresponding provision of a successor statute.
Conference Objectives are :
At the conclusion of the TRS 2018 Annual Scientific & Business Meeting, attendees will be able to:
• Explain the controversy surrounding the definition of vitamin D status and understand the reason(s) for this.
• Appreciate the challenges/limitations of 25(OH)D measurement and a reasonable approach to defining “optimal” vitamin D status.
• Review the different antiphospholipid antibodies.
• Evaluate the non-thrombotic manifestations seen by Rheumatologists.
• Describe the controversy of DOACs for APS.
• Evaluate the definition of “osteoporosis” and consider whether this definition should be expanded.
• Appreciate the importance of sarcopenia and other co-morbidities as contributors of the syndrome of “osteoporosis-related” fracture.
• Evaluate the price patients pay for reliance on steroids.
• Review recent data on non immunosuppressive immunomodulators, not just hydroxychloroquine, but also vitamin D.
• Evaluate Phase 2 trial results for both lupus nephritis and non-renal lupus—the future is exciting!
• Describe what small RNAs are and their potential as disease biomarkers.
• Explain differences in the classification and complications of juvenile idiopathic arthritis compared to adult-onset inflammatory arthritis.
• Recognize available resources that can be used to facilitate the care of teens and young adults from pediatric to adult systems.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Rheumatologists, physicians engaged in the ongoing practice of rheumatology. This CME Conference has been approved for a maximum of 6.75 AMA PRA Category 1 Credits.
Conference Description :
The purpose is to increase and propagate the understanding of rheumatic diseases among physicians engaged in the ongoing practice of rheumatology and the socio-economic issues involved in the treatment of these diseases, and other lawful purposes; provided, however, that all purposes of the Corporation are and shall remain exclusively charitable, scientific, religious or educational and otherwise within the meaning of Section 501(c)(3) corresponding provision of a successor statute.
Conference Objectives are :
At the conclusion of the TRS 2018 Annual Scientific & Business Meeting, attendees will be able to:
• Explain the controversy surrounding the definition of vitamin D status and understand the reason(s) for this.
• Appreciate the challenges/limitations of 25(OH)D measurement and a reasonable approach to defining “optimal” vitamin D status.
• Review the different antiphospholipid antibodies.
• Evaluate the non-thrombotic manifestations seen by Rheumatologists.
• Describe the controversy of DOACs for APS.
• Evaluate the definition of “osteoporosis” and consider whether this definition should be expanded.
• Appreciate the importance of sarcopenia and other co-morbidities as contributors of the syndrome of “osteoporosis-related” fracture.
• Evaluate the price patients pay for reliance on steroids.
• Review recent data on non immunosuppressive immunomodulators, not just hydroxychloroquine, but also vitamin D.
• Evaluate Phase 2 trial results for both lupus nephritis and non-renal lupus—the future is exciting!
• Describe what small RNAs are and their potential as disease biomarkers.
• Explain differences in the classification and complications of juvenile idiopathic arthritis compared to adult-onset inflammatory arthritis.
• Recognize available resources that can be used to facilitate the care of teens and young adults from pediatric to adult systems.
Additional details will be posted as soon as they are available.
KEY DATES
23 Feb, 2018
Event Start Date
24 Feb, 2018
Event End Date
SPECIALITIES
RheumatologySUGGESTED HOTELS
CONFERENCE VENUE
Franklin Marriott Cool SpringsRELATED CONFERENCES & LIVE WEBINARS
Quick Links